Intelligent Bio Solutions Third Quarter 2025 Earnings: US$0.44 loss per share (vs US$1.43 loss in 3Q 2024)

Simply Wall St

May 15, 2025

Intelligent Bio Solutions (NASDAQ:INBS) Third Quarter 2025 Results

Key Financial Results

Revenue: US$728.9k (down 12% from 3Q 2024).
Net loss: US$2.54m (loss narrowed by 15% from 3Q 2024).
US$0.44 loss per share (improved from US$1.43 loss in 3Q 2024).

Our free stock report includes 6 warning signs investors should be aware of before investing in Intelligent Bio Solutions. Read for free now.

earnings-and-revenue-history — NasdaqCM:INBS Earnings and Revenue History May 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Intelligent Bio Solutions shares are up 12% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 6 warning signs for Intelligent Bio Solutions you should be aware of, and 4 of them are a bit unpleasant.

If you're looking to trade Intelligent Bio Solutions, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.